Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | microtubule-associated protein tau | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | microtubule-associated protein tau | 0.0833 | 1 | 1 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0273 | 0.2803 | 0.5 |
Echinococcus multilocularis | lysosomal protective protein | 0.0273 | 0.2803 | 0.2803 |
Echinococcus granulosus | lysosomal protective protein | 0.0273 | 0.2803 | 0.2803 |
Onchocerca volvulus | Uncharacterized serine carboxypeptidase homolog | 0.0273 | 0.2803 | 0.5 |
Schistosoma mansoni | family S10 non-peptidase homologue (S10 family) | 0.0273 | 0.2803 | 0.2803 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S10, putative | 0.0273 | 0.2803 | 0.5 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0273 | 0.2803 | 0.5 |
Echinococcus multilocularis | family S10 non peptidase ue (S10 family) | 0.0246 | 0.2456 | 0.2456 |
Trypanosoma cruzi | serine carboxypeptidase (CBP1), putative | 0.0273 | 0.2803 | 0.5 |
Brugia malayi | Serine carboxypeptidase F41C3.5 precursor | 0.0273 | 0.2803 | 1 |
Leishmania major | serine carboxypeptidase (CBP1), putative,serine peptidase, Clan SC, Family S10 | 0.0273 | 0.2803 | 0.5 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S10, putative | 0.0273 | 0.2803 | 0.5 |
Trypanosoma cruzi | serine carboxypeptidase (CBP1), putative | 0.0273 | 0.2803 | 0.5 |
Echinococcus granulosus | family S10 non peptidase ue S10 family | 0.0246 | 0.2456 | 0.2456 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.0833 | 1 | 1 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0273 | 0.2803 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.2803 | 1 |
Schistosoma mansoni | family S10 unassigned peptidase (S10 family) | 0.0273 | 0.2803 | 0.2803 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 53 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule agonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | > 47.1 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule antagonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.